PD-(L)1 x VEGF bispecifics prove a big draw.
ApexOnco Front Page
Recent articles
7 July 2025
Bezuclastinib's registrational trial meets predefined success criteria, with a big spotlight on toxicity.
26 June 2025
The company reckons its immunotherapy could improve on Keytruda.
25 June 2025
“We need all the capital we can get our hands on," the company states.
24 June 2025
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
24 June 2025
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
23 June 2025
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
23 June 2025
Sunmo succeeds in a setting very similar to Starglo's.